AZ, Daiichi’s new cancer drug Enhertu gets off to the races with quick U.S. launch
admin 10th February 2020 Uncategorised 0What do you get when you add a drug with clear clinical benefits, an extremely early FDA nod and two well-prepared sales teams? In Daiichi Sankyo and AstraZeneca’s HER2-targeting med Enhertu’s case, a potential $18 million in sales during the first quarter of launch.
More: AZ, Daiichi’s new cancer drug Enhertu gets off to the races with quick U.S. launch
Source: fierce